Literature DB >> 18665146

Treatment recommendations for migraine.

Stephen D Silberstein1.   

Abstract

The pharmacological treatment of migraine can be acute or preventive. Acute treatment attempts to stop the progression of an attack or relieve pain and functional impairment once an attack has begun, whereas preventive therapy is given to reduce attack frequency and severity. Additional benefits of preventive therapy include improving responsiveness to acute attack treatment, and reducing disability. Treatment protocols should also include education and reassurance, avoidance of triggers, nonpharmacological treatments, and physical and/or complementary medicine when appropriate. The treatment plan should be reassessed at regular intervals. Acute attack medication can be specific or nonspecific, and needs to be tailored to the individual patient. Backup and rescue medication should be available in case the initial treatment fails. The route of drug administration depends on attack severity, how rapidly the attack escalates, the patient's preference, the presence or absence of severe nausea or vomiting, and the need for rapid relief. Preventive migraine treatments include beta-blockers, antidepressants, calcium channel antagonists, 5-hydroxytryptamine antagonists, anticonvulsants, and NSAIDs. Preventive treatments are selected on the basis of the drugs' side-effect profiles and the patient's coexistent and comorbid conditions.

Entities:  

Mesh:

Year:  2008        PMID: 18665146     DOI: 10.1038/ncpneuro0861

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


  10 in total

1.  Prenatal antiepileptic exposure associates with neonatal DNA methylation differences.

Authors:  Alicia K Smith; Karen N Conneely; D Jeffrey Newport; Varun Kilaru; James W Schroeder; Page B Pennell; Bettina T Knight; Joseph C Cubells; Zachary N Stowe; Patricia A Brennan
Journal:  Epigenetics       Date:  2012-05-01       Impact factor: 4.528

2.  The association of migraine with menstrually related mood disorders and childhood sexual abuse.

Authors:  Adomas Bunevicius; David R Rubinow; Anne Calhoun; Jane Leserman; Erin Richardson; Kim Rozanski; Susan S Girdler
Journal:  J Womens Health (Larchmt)       Date:  2013-08-09       Impact factor: 2.681

3.  Critical role of calcitonin gene-related peptide receptors in cortical spreading depression.

Authors:  Alessandro Tozzi; Antonio de Iure; Massimiliano Di Filippo; Cinzia Costa; Stefano Caproni; Antonio Pisani; Paola Bonsi; Barbara Picconi; Letizia M Cupini; Serena Materazzi; Pierangelo Geppetti; Paola Sarchielli; Paolo Calabresi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-29       Impact factor: 11.205

4.  Naturalistic assessment of patterns and predictors of acute headache medication use among women with comorbid migraine and overweight or obesity.

Authors:  Kathryn E Smith; J Graham Thomas; Kristine J Steffen; Richard B Lipton; Samantha G Farris; Jelena M Pavlovic; Dale S Bond
Journal:  Transl Behav Med       Date:  2021-08-13       Impact factor: 3.046

5.  Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine.

Authors:  Carrie E Robertson; Ivan Garza
Journal:  Neuropsychiatr Dis Treat       Date:  2012-01-13       Impact factor: 2.570

6.  Do Molecular Structures of Migraine Drugs Point to a Common Cause of this Elusive Disease and Suggest Future Drug Designs?

Authors:  Mark J Brinsden; Ian C Shaw
Journal:  Pharmaceut Med       Date:  2015

Review 7.  Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins.

Authors:  Sara M Schaefer; Christopher H Gottschalk; Bahman Jabbari
Journal:  Toxins (Basel)       Date:  2015-07-14       Impact factor: 4.546

Review 8.  [Formalized consensus: clinical practice recommendations for the management of the migraine in African adult patients].

Authors:  Mahmoud Ait Kaci Ahmed; Monia Haddad; Beugré Kouassi; Hamid Ouhabi; Alain Serrie
Journal:  Pan Afr Med J       Date:  2016-05-25

9.  Increased risk of essential tremor in migraine: A population-based retrospective cohort study.

Authors:  Chi-Ieong Lau; Che-Chen Lin; Hsuan-Ju Chen; Han-Cheng Wang; Wei-Hung Chen; Ji-An Liang
Journal:  PLoS One       Date:  2017-03-13       Impact factor: 3.240

10.  Patient outcome in migraine prophylaxis: the role of psychopharmacological agents.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Giulia Serra; Giovanni Dominici; Juliana Fortes-Lindau; Monica Pastina; Ludovica Telesforo; David Lester; Paolo Girardi; Roberto Tatarelli; Paolo Martelletti
Journal:  Patient Relat Outcome Meas       Date:  2010-09-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.